These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 12773962

  • 1. The problem of late allograft loss in kidney transplantation.
    Cardarelli F, Saidman S, Theruvath T, Tolkoff-Rubin N, Cosimi AB, Pascual M.
    Minerva Urol Nefrol; 2003 Mar; 55(1):1-11. PubMed ID: 12773962
    [Abstract] [Full Text] [Related]

  • 2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B, Höcker B.
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [Abstract] [Full Text] [Related]

  • 3. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM, Kobashigawa J, Klintmalm G.
    Clin Transplant; 2008 Sep; 22(1):1-15. PubMed ID: 18217899
    [Abstract] [Full Text] [Related]

  • 4. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 5. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 6. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR, Ghafari A, Hajizadeh E, Kazemnejad A.
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [Abstract] [Full Text] [Related]

  • 7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 8. [Causes of late renal transplant dysfunction].
    Szabó A, Müller V.
    Orv Hetil; 2002 Dec 22; 143(51):2811-9. PubMed ID: 12638307
    [Abstract] [Full Text] [Related]

  • 9. Molecular and structural consequences of early renal allograft injury.
    Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA.
    Kidney Int; 2002 Feb 22; 61(2):686-96. PubMed ID: 11849412
    [Abstract] [Full Text] [Related]

  • 10. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM, Grinyó JM.
    Transplantation; 2001 Jun 15; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [Abstract] [Full Text] [Related]

  • 11. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
    Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC.
    Am J Nephrol; 2004 Jun 15; 24(4):379-86. PubMed ID: 15237243
    [Abstract] [Full Text] [Related]

  • 12. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Malik T, Wrenshall LE.
    PLoS One; 2015 Jun 15; 10(10):e0139247. PubMed ID: 26465152
    [Abstract] [Full Text] [Related]

  • 13. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ.
    Transplantation; 2007 Mar 27; 83(6):722-6. PubMed ID: 17414704
    [Abstract] [Full Text] [Related]

  • 14. The natural history of chronic allograft nephropathy.
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR.
    N Engl J Med; 2003 Dec 11; 349(24):2326-33. PubMed ID: 14668458
    [Abstract] [Full Text] [Related]

  • 15. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ.
    Transplantation; 2007 Apr 15; 83(7):883-92. PubMed ID: 17460558
    [Abstract] [Full Text] [Related]

  • 16. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC.
    Kidney Int; 2001 Apr 15; 59(4):1567-73. PubMed ID: 11260422
    [Abstract] [Full Text] [Related]

  • 17. Is cyclosporine withdrawal a therapeutic option in renal transplant recipients with chronic allograft dysfunction?
    Ducloux D.
    Minerva Urol Nefrol; 2003 Mar 15; 55(1):81-9. PubMed ID: 12773969
    [Abstract] [Full Text] [Related]

  • 18. Chronic renal allograft rejection: pathophysiologic considerations.
    Joosten SA, Sijpkens YW, van Kooten C, Paul LC.
    Kidney Int; 2005 Jul 15; 68(1):1-13. PubMed ID: 15954891
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus in chronic allograft nephropathy.
    Wu MJ, Shu KH, Cheng CH, Chen CH.
    Transplant Proc; 2004 Sep 15; 36(7):2053-5. PubMed ID: 15518743
    [Abstract] [Full Text] [Related]

  • 20. Chronic allograft nephropathy.
    Najafian B, Kasiske BL.
    Curr Opin Nephrol Hypertens; 2008 Mar 15; 17(2):149-55. PubMed ID: 18277147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.